EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Calcitonin gene-related peptide monoclonal antibodies and medication overuse headache: is stopping excessive pain medication still necessary?

João José Freitas de Carvalho iD

Arquivos de Neuro-Psiquiatria · 01.09.2025 · 83 (09) · 001-003

DOI: 10.1055/s-0045-1809658 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Arquivos de Neuro-Psiquiatria, erschienen am 01.09.2025. Verfasst von João José Freitas de Carvalho. Beteiligte Einrichtung: Faculdade de Medicina Unichristus, Fortaleza CE, Brazil. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Headache Disorders, Secondary, Antibodies, Monoclonal, Migraine Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent studies demonstrate a significant paradigm shift concerning migraine patients suffering from medication overuse (MO). Traditionally, doctors used to demand that patients who overused medications be withdrawn before beginning any preventive therapy; however, such a belief has recently been challenged by emerging evidence about the benefit of calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs), which have shown similar effectiveness in several clinical trials and real-world studies, regardless of whether a patient has previously stopped taking excessive medications. The data indicates that patients undergoing CGRP mAb therapy naturally decreased their acute medication consumption as migraine frequency diminished without requiring forced discontinuation. Furthermore, safety analyses have confirmed favorable tolerability profiles when CGRP mAbs are administered concurrently with various acute medications. This new evidence-based approach offers several clinical advantages, including enhanced treatment adherence and reduced risk of withdrawal complications. These findings support transitioning from mandatory detoxification protocols toward more individualized treatment strategies, representing a significant advancement in clinical migraine management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related PeptideHeadache Disorders, SecondaryAntibodies, MonoclonalMigraine DisordersHumans

Substanzen

Calcitonin Gene-Related PeptideAntibodies, Monoclonal

Autor:innen und Institutionen

  • Faculdade de Medicina Unichristus, Fortaleza CE, Brazil.

ORCID-Profile: João José Freitas de Carvalho

Zitieren

APA

Carvalho, J. J. F. (2025). Calcitonin gene-related peptide monoclonal antibodies and medication overuse headache: is stopping excessive pain medication still necessary?. Arquivos de Neuro-Psiquiatria, 83(09), 001-003. https://doi.org/10.1055/s-0045-1809658

Vancouver

Carvalho JJF. Calcitonin gene-related peptide monoclonal antibodies and medication overuse headache: is stopping excessive pain medication still necessary?. Arquivos de Neuro-Psiquiatria. 2025;83(09):001-003. doi:10.1055/s-0045-1809658

BibTeX
@article{Carvalho2025,
  author = {Carvalho, João José Freitas de},
  title = {Calcitonin gene-related peptide monoclonal antibodies and medication overuse headache: is stopping excessive pain medication still necessary?},
  journal = {Arquivos de Neuro-Psiquiatria},
  year = {2025},
  volume = {83},
  number = {09},
  pages = {001--003},
  doi = {10.1055/s-0045-1809658}
}
Kostenlos starten →